Background: Pentoxifylline is a methylxanthine derivative with significant anti-inflammatory, anti-fibrotic, and anti-proliferative properties. Studies have shown that pentoxifylline may have renoprotective effects in patients with diabetic nephropathy. However, most of these studies were limited by small sample sizes. Therefore, we investigated whether pentoxifylline could reduce proteinuria in patients with diabetic nephropathy and residual proteinuria who received an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB). We also studied the effects of pentoxifylline on glycemic control, insulin resistance, and inflammatory parameters.
Methods: This was a prospective, randomized double-blind, placebo-controlled, multi-center study. A total of 174 patients with type 2 diabetes and albuminuria (>30 mg/g of creatinine) who were taking the recommended dosage of ACEI or ARB for > 6 months and receiving conventional therapy for diabetes were randomly assigned to receive pentoxifylline (1200 mg, daily; n = 87) or a placebo (n = 87) for 6 months. The endpoints were the effects of pentoxifylline on proteinuria, renal function, glucose control, and inflammatory parameters.
Results: The percentage changes in proteinuria from baseline in the pentoxifylline and placebo groups were a decrease of 23 % and 4 %, respectively (p = 0.012). In addition, significant reductions in fasting plasma glucose, glycated hemoglobin, and insulin resistance according to the homeostasis model assessment were observed in the pentoxifylline group compared to those in the placebo group. However there was no significant difference in serum tumor necrosis factor (TNF)-α between the groups.
Conclusions: Pentoxifylline therapy reduced proteinuria and improved glucose control and insulin resistance without significant change of serum TNF-α in patients with type 2 diabetic nephropathy. Therefore, pentoxifylline is a potential therapeutic alternative for treating diabetes and diabetic nephropathy.
Trial Registration: NCT01382303.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546105 | PMC |
| http://dx.doi.org/10.1186/s13098-015-0060-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of L-carnitine and pentoxifylline on long-term preservation of the human sperms: An experimental study.
Int J Reprod Biomed
November 2024
Histomorphometry and Stereology Research Center, Anatomy Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: In infertility clinics, long-time preserving high-quality spermatozoa is a challenging problem.
Objective: The present study aimed to prolong preserving of the human spermatozoa by adding pentoxifylline (PT) and L-carnitine (LC) without using high-cost freezing techniques.
Materials And Methods: In this experimental study, semen samples of 26 normozoospermia men aged between 28-34 yr, were firstly prepared using the swim-up technique, and each sample was divided into the following 3 aliquots: untreated control group, the LC, and PT-treated groups.
Efficacy of intralesional pentoxifylline versus intralesional steroid versus intralesional vitamin D in treatment of keloid.
Arch Dermatol Res
January 2025
Medicine and General Surgery, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Several treatment modalities have been used for the treatment of keloid scarring but the optimal treatment has not yet been identified. Corticosteroids reduce excessive scarring by reducing collagen synthesis. Vitamin D can curb inflammation by inhibiting the activation and migration of leukocytes.
View Article and Find Full Text PDFManaging strategies of chemotherapy and radiotherapy-induced oral mucositis.
Cancer Treat Rev
January 2025
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China. Electronic address:
Radiotherapy and chemotherapy are widely employed as primary non-surgical cancer treatments; however, their non-selective cytotoxicity often leads to adverse events such as oral mucositis (OM), particularly in head and neck cancer therapies. International guidelines provide recommendations for managing chemoradiotherapy-induced OM in various clinical contexts. Subsequently, emerging researches have introduced evidence supporting novel approaches or existing regimens for OM prevention and treatment.
View Article and Find Full Text PDFBackground: Chronic inflammation has been linked to many psychiatric disorders, and therefore, pertinent anti-inflammatory therapies have been empirically evaluated for management. An enduring example of long-term safety, attainability, and versatility has been pentoxifylline (PTX). PTX is a phosphodiesterase inhibitor that modulates inflammatory mediators and affects most blood components and the blood vessels.
View Article and Find Full Text PDFRepurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease.
Gut Liver
January 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Alcohol-related liver disease (ALD) is a serious global health concern, characterized by liver inflammation and progressive fibrosis. There are no Food and Drug Administration-approved drugs, thus effective treatments are needed. Severe alcoholic hepatitis (AH) is the most severe manifestation of ALD, with a 28-day mortality rate ranging from 20% to 50%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!